Plain-English translation of NCT06835049 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Soft tissue sarcoma is a rare cancer with a 5-year survival rate of about 60%. This trial is testing whether combining (a chemotherapy drug) with moderate regional hyperthermia (controlled heat therapy) can improve survival. The goal is to determine if this new combined approach works well and is practical for patients to receive.
Current treatment for high-risk soft tissue sarcoma doesn't have a clear best approach. Earlier research suggests that adding heat therapy to chemotherapy may improve survival by about 10%, but this combined treatment hasn't been thoroughly tested yet. This trial aims to see if this promising approach is feasible and safe to offer to patients.
You likely qualify if…
You likely don't qualify if…
Over approximately 20 weeks, you will receive three cycles of chemotherapy (combined with heat therapy sessions) — each cycle lasting 3 weeks. After chemotherapy, you will receive radiation therapy followed by surgery to remove the tumor. Then you will be followed for 3 years with regular check-ups to monitor how well the treatment worked and how you are doing.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
Switzerland